Skip to main content

Table 5 Treatment-related adverse events

From: Lapatinib in combination with capecitabine versus continued use of trastuzumab in breast cancer patients with trastuzumab-resistance: a retrospective study of a Chinese population

 

LX

TBP

(N = 236)

(N = 296)

 

grade1–2

grade3–4

grade1–2

grade3–4

Neutropenia

24(10.2%)

5(2.1%)

87(29.4%)

19(6.4%)

Febrile neutropenia

4(1.7%)

0(0.0%)

20(6.8%)

4(1.4%)

Thrombocytopenia

12(5.1%)

1(0.4%)

25(8.4%)

3(1%)

Anemia

4(1.7%)

0(0.0%)

40(13.5%)

0(0.0%)

Nausea/Vomiting

60(25.4%)

0(0.0%)

56(18.9%)

8(2.7%)

Diarrhea

92(39.0%)

12(5.1%)

15(5.1%)

0(0.0%)

Cardiac toxicity

0(0.0%)

0(0.0%)

2(0.7%)

0(0.0%)

Rash or erythema

45(19.1%)

0(0.0%)

13(4.4%)

0(0.0%)

ALT/AST increased

28(11.9%)

0(0.0%)

32(10.8%)

27(9.1%)

Hand–foot syndrome

56(23.7%)

24(10.2%)

7(2.4%)

0(0.0%)

  1. Abbreviations: NCI CTCAE National Cancer Institute Common Terminology Criteria of Adverse Events